Mortality and morbidity in adult craniopharyngioma

被引:0
作者
Eva Marie Erfurth
Helene Holmer
Sigridur Bara Fjalldal
机构
[1] Skånes University Hospital,Department of Endocrinology
[2] Centralsjukhuset,Department of Internal Medicine
来源
Pituitary | 2013年 / 16卷
关键词
Mortality; Morbidity; Hypothalamic damage; Hypopituitarism; Cardiovascular risk; Quality of life; Cognitive function;
D O I
暂无
中图分类号
学科分类号
摘要
A craniopharyngioma (CP) is an embryonic malformation of the sellar and parasellar region. The annual incidence is 0.5–2.0 cases/million/year and approximately 60 % of CP are seen in adulthood. Craniopharyngiomas have the highest mortality of all pituitary tumors. Typical initial manifestations at diagnosis in adults are visual disturbances, hypopituitarism and symptoms of elevated intracranial pressure. The long-term morbidity is substantial with hypopituitarism, increased cardiovascular risk, hypothalamic damage, visual and neurological deficits, reduced bone health, and reduction in quality of life and cognitive function. Therapy of choice is surgery, followed by cranial radiotherapy in about half of the patients. The standardised overall mortality rate varies 2.88–9.28 in cohort studies. Patients with CP have a 3–19 fold higher cardiovascular mortality in comparison to the general population. Women with CP have an even higher risk.
引用
收藏
页码:46 / 55
页数:9
相关论文
共 515 条
  • [81] Pereira AM(2004)Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H) J Clin Endocrinol Metab 89 1684-S68
  • [82] Schmid EM(2000)The psychological consequences and quality of life in adults with growth hormone deficiency Growth Horm IGF Res 10 S63-370
  • [83] Schutte PJ(2002)The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults Clin Endocrinol (Oxf) 57 363-3189
  • [84] Voormolen JH(1998)Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficit J Clin Endocrinol Metab 83 3184-undefined
  • [85] Biermasz NR(undefined)undefined undefined undefined undefined-undefined
  • [86] van Thiel SW(undefined)undefined undefined undefined undefined-undefined
  • [87] Corssmit EP(undefined)undefined undefined undefined undefined-undefined
  • [88] Smit JW(undefined)undefined undefined undefined undefined-undefined
  • [89] Roelfsema F(undefined)undefined undefined undefined undefined-undefined
  • [90] Romijn JA(undefined)undefined undefined undefined undefined-undefined